organization · Reporting owner

Ponoi Management, LLC

Disclosed activity across 7 companies

Tapewire entity: 84822
SEC CIK: 0001720702

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CONSTELLATION PHARMACEUTICALS INCCNST · Entity 137050	10% owner	February 17, 2021	February 19, 2021
NGM BIOPHARMACEUTICALS INCNGM · Entity 11997	10% owner	April 05, 2024	April 08, 2024
Revolution Medicines, Inc.RVMD · Entity 606	10% owner	November 16, 2020	November 18, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CONSTELLATION PHARMACEUTICALS INC

Report date February 17, 2021 · Filed February 19, 2021

Jointly reported with COLUMN GROUP L P, COLUMN GROUP III, LP, COLUMN GROUP III-A, LP, COLUMN GROUP III GP, LP, COLUMN GROUP GP, LP, PONOI CAPITAL, LP, Ponoi Capital II, LP, Ponoi II Management, LLC, Kutzkey Tim

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	99,155	Reported balance After 2021-02-17 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2021-02-17 · Sale · Disposed 10,000 · Balance 99,155 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $36.95 to $37.005, inclusive. The David V. and Alena Z. Goeddel 2004 Trust undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: These securities are held directly by The David V. and Alena Z. Goeddel 2004 Trust.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,880,623	Reported balance Holding disclosure · report date 2021-02-17 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,880,623 F4: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson, and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,574,229	Reported balance Holding disclosure · report date 2021-02-17 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 1,574,229 F5: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	19,571	Reported balance Holding disclosure · report date 2021-02-17 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 19,571 F6: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Ponoi Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	22,103	Reported balance Holding disclosure · report date 2021-02-17 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 22,103 F7: The securities are directly held by The Column Group III- A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Ponoi Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	50,000	Reported balance Holding disclosure · report date 2021-02-17 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 50,000 F8: These securities are held directly by the Alena Goeddel Irrevocable Trust
Common StockSEC Table I · non-derivative	Direct	2,584,957	Reported balance Holding disclosure · report date 2021-02-17 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 2,584,957 F3: These securities are directly held by The Column Group, LP ("TCG LP"). The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $36.95 to $37.005, inclusive. The David V. and Alena Z. Goeddel 2004 Trust undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2: These securities are held directly by The David V. and Alena Z. Goeddel 2004 Trust.

F3: These securities are directly held by The Column Group, LP ("TCG LP"). The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F4: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson, and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares

F5: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F6: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Ponoi Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F7: The securities are directly held by The Column Group III- A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Ponoi Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F8: These securities are held directly by the Alena Goeddel Irrevocable Trust

NGM BIOPHARMACEUTICALS INC

Report date April 05, 2024 · Filed April 08, 2024

Jointly reported with COLUMN GROUP L P, Svennilson Peter, Kutzkey Tim, Ponoi Capital II, LP, Ponoi II Management, LLC, PONOI CAPITAL, LP, COLUMN GROUP II, LP, Column Group Management LP, Column Group II GP, LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	0	Reported balance After 2024-04-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-04-05 · Disposition to issuer · Disposed 949,862 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3) F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-04-05 · Disposition to issuer · Disposed 2,650,177 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2024-04-05 · Disposition to issuer · Disposed 90,442 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2024-04-05 · Disposition to issuer · Disposed 858,035 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2024-04-05 · Disposition to issuer · Disposed 968,990 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2024-04-05 · Disposition to issuer · Disposed 2,265,758 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 9 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 10 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 11 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 12 · 2024-04-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F15: The securities were owned solely by Tim Kutzkey.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 13 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 13 · 2024-04-05 · Disposition to issuer · Disposed 44,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F16: The securities were directly held by Peter Svennilson.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,000	Reported balance After 2024-04-05 transaction · row 14 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 14 · 2024-04-05 · Other · Acquired 1,000 · Balance 1,000 F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-04-05 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2024-04-05 · Disposition to issuer · Disposed 11,103,333 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3)

F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F15: The securities were owned solely by Tim Kutzkey.

F16: The securities were directly held by Peter Svennilson.

F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.

Revolution Medicines, Inc.

Report date November 16, 2020 · Filed November 18, 2020

Jointly reported with COLUMN GROUP III, LP, COLUMN GROUP III-A, LP, COLUMN GROUP III GP, LP, PONOI CAPITAL, LP, Ponoi Capital II, LP, Ponoi II Management, LLC, Kutzkey Tim, GOEDDEL DAVID V

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,151,026	Reported balance After 2020-11-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-11-16 · Sale · Disposed 952,023 · Balance 2,151,026 F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson, a member of the Issuer's board of directors, and Tim Kutzkey (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,429,180	Reported balance After 2020-11-16 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2020-11-16 · Sale · Disposed 1,075,133 · Balance 2,429,180 F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares
Common StockSEC Table I · non-derivative	IndirectSee Footnote	685,011	Reported balance Holding disclosure · report date 2020-11-16 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 685,011 F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares
Common StockSEC Table I · non-derivative	IndirectSee Footnote	685,011	Reported balance Holding disclosure · report date 2020-11-16 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 685,011 F4: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson, a member of the Issuer's board of directors, and Tim Kutzkey (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares

F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares

F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares

F4: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Arcus Biosciences, Inc.

Report date March 19, 2018 · Filed March 19, 2018

Jointly reported with COLUMN GROUP II, LP, Column Group II GP, LP, PONOI CAPITAL, LP, GOEDDEL DAVID V, Svennilson Peter, Kutzkey Tim

Section 16 reporting ended · disclosed 2018-03-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,767,676	Reported balance After 2018-03-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-03-19 · Conversion · Acquired 1,767,676 · Balance 1,767,676 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares
Common StockSEC Table I · non-derivative	Direct	2,642,763	Reported balance After 2018-03-19 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-03-19 · Conversion · Acquired 875,087 · Balance 2,642,763 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares
Common StockSEC Table I · non-derivative	Direct	3,070,423	Reported balance After 2018-03-19 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-03-19 · Conversion · Acquired 427,660 · Balance 3,070,423 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares
Common StockSEC Table I · non-derivative	Direct	470,427	Reported balance After 2018-03-19 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2018-03-19 · Conversion · Acquired 470,427 · Balance 470,427 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP") and indirectly held by Ponoi Management, LLC ("Ponoi LLC") the general partner of Ponoi LP. Ponoi LLC has voting and dispositive power with respect to these shares. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-03-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-03-19 · Conversion · Disposed 1,767,676 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-03-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-03-19 · Conversion · Disposed 875,087 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-03-19 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-03-19 · Conversion · Disposed 427,660 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-03-19 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-03-19 · Conversion · Disposed 470,427 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP") and indirectly held by Ponoi Management, LLC ("Ponoi LLC") the general partner of Ponoi LP. Ponoi LLC has voting and dispositive power with respect to these shares. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.

F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares

F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP") and indirectly held by Ponoi Management, LLC ("Ponoi LLC") the general partner of Ponoi LP. Ponoi LLC has voting and dispositive power with respect to these shares. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

IMMUNE DESIGN CORP.

Report date April 02, 2019 · Filed April 02, 2019

Jointly reported with COLUMN GROUP L P, COLUMN GROUP GP, LP, COLUMN GROUP II, LP, Column Group II GP, LP, PONOI CAPITAL, LP, GOEDDEL DAVID V, Kutzkey Tim, Svennilson Peter

Section 16 reporting ended · disclosed 2019-04-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-04-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-04-02 · Other · Disposed 6,642,942 · Balance 0 F1: Includes shares directly held by Ponoi Capital LP ("Ponoi LP"), The Column Group II, LP ("TCG II LP") and The Column Group, LP ("TCG LP"). The Column Group II GP, LP ("TCG II GP"), as the general partner of TCG II LP, has voting and dispositive power with respect to certain of the shares. The Column Group GP, LP ("TCG GP"), as the general partner of TCG LP, has voting and dispositive power with respect to certain of the shares. Ponoi Management, LLC ("Ponoi LLC"), as the general partner of Ponoi LP, has voting and dispositive power with respect to certain of the shares. F2: (cont.) The individual managing partners of both TCG II GP and TCG GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting and dispositive power with respect to the shares owned by TCG II LP and TCG LP. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting and dispositive power with respect to the shares owned by Ponoi LP. Each individual managing partner disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: Includes shares directly held by Ponoi Capital LP ("Ponoi LP"), The Column Group II, LP ("TCG II LP") and The Column Group, LP ("TCG LP"). The Column Group II GP, LP ("TCG II GP"), as the general partner of TCG II LP, has voting and dispositive power with respect to certain of the shares. The Column Group GP, LP ("TCG GP"), as the general partner of TCG LP, has voting and dispositive power with respect to certain of the shares. Ponoi Management, LLC ("Ponoi LLC"), as the general partner of Ponoi LP, has voting and dispositive power with respect to certain of the shares.

F2: (cont.) The individual managing partners of both TCG II GP and TCG GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting and dispositive power with respect to the shares owned by TCG II LP and TCG LP. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting and dispositive power with respect to the shares owned by Ponoi LP. Each individual managing partner disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest in such shares.

Nurix Therapeutics, Inc.

Report date May 07, 2021 · Filed May 07, 2021

Jointly reported with COLUMN GROUP L P, COLUMN GROUP GP, LP, COLUMN GROUP II, LP, Column Group II GP, LP, PONOI CAPITAL, LP, Ponoi II Management, LLC, Ponoi Capital II, LP, Kutzkey Tim, GOEDDEL DAVID V

Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,394,333	Reported balance After 2021-05-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-05-05 · Other · Disposed 2,000,000 · Balance 1,394,333 F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group, LP ("TCG LP") to its general and limited partners. F2: The securities are directly held by TCG LP, and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson (the "Managing Partners"). The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	438,338	Reported balance After 2021-05-05 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2021-05-05 · Other · Acquired 438,338 · Balance 438,338 F3: Represents a change in the form of ownership of TCG GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F4: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	10,307	Reported balance After 2021-05-05 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2021-05-05 · Other · Acquired 10,307 · Balance 10,307 F5: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F6: The securities are directly held by Peter Svennilson
Common StockSEC Table I · non-derivative	IndirectSee Footnote	10,307	Reported balance After 2021-05-05 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2021-05-05 · Other · Acquired 10,307 · Balance 10,307 F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F8: The securities are directly held by David Goeddel.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	10,307	Reported balance After 2021-05-05 transaction · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · 2021-05-05 · Other · Acquired 10,307 · Balance 10,307 F9: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F10: The securities are directly held by Tim Kutzkey.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2021-05-05 transaction · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · 2021-05-05 · Other · Disposed 438,338 · Balance 0 F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG GP to its general and limited partners. F4: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	116,181	Reported balance After 2021-05-05 transaction · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · 2021-05-05 · Other · Acquired 105,874 · Balance 116,181 F12: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP. F6: The securities are directly held by Peter Svennilson
Common StockSEC Table I · non-derivative	IndirectSee Footnote	121,554	Reported balance After 2021-05-05 transaction · row 8 Holding and transaction disclosures are not merged. 1 source row Row 8 · 2021-05-05 · Other · Acquired 111,247 · Balance 121,554 F13: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP. F8: The securities are directly held by David Goeddel.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	40,654	Reported balance After 2021-05-05 transaction · row 9 Holding and transaction disclosures are not merged. 1 source row Row 9 · 2021-05-05 · Other · Acquired 30,347 · Balance 40,654 F14: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP. F10: The securities are directly held by Tim Kutzkey.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	989,000	Reported balance After 2021-05-05 transaction · row 10 Holding and transaction disclosures are not merged. 1 source row Row 10 · 2021-05-05 · Other · Disposed 1,000,000 · Balance 989,000 F15: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners. F16: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are the Managing Partners. The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	49,689	Reported balance After 2021-05-05 transaction · row 11 Holding and transaction disclosures are not merged. 1 source row Row 11 · 2021-05-05 · Other · Acquired 49,689 · Balance 49,689 F17: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP. F18: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2021-05-05 transaction · row 12 Holding and transaction disclosures are not merged. 1 source row Row 12 · 2021-05-05 · Other · Disposed 49,689 · Balance 0 F19: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its general and limited partners. F18: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	134,010	Reported balance After 2021-05-05 transaction · row 13 Holding and transaction disclosures are not merged. 1 source row Row 13 · 2021-05-05 · Other · Acquired 17,829 · Balance 134,010 F20: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F6: The securities are directly held by Peter Svennilson
Common StockSEC Table I · non-derivative	IndirectSee Footnote	139,383	Reported balance After 2021-05-05 transaction · row 14 Holding and transaction disclosures are not merged. 1 source row Row 14 · 2021-05-05 · Other · Acquired 17,829 · Balance 139,383 F21: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F8: The securities are directly held by David Goeddel.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	48,406	Reported balance After 2021-05-05 transaction · row 15 Holding and transaction disclosures are not merged. 1 source row Row 15 · 2021-05-05 · Other · Acquired 7,752 · Balance 48,406 F22: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F10: The securities are directly held by Tim Kutzkey.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	686,274	Reported balance Holding disclosure · report date 2021-05-07 · row 16 Holding and transaction disclosures are not merged. 1 source row Row 16 · Balance 686,274 F23: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"), and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	686,274	Reported balance Holding disclosure · report date 2021-05-07 · row 17 Holding and transaction disclosures are not merged. 1 source row Row 17 · Balance 686,274 F24: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"), and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group, LP ("TCG LP") to its general and limited partners.

F2: The securities are directly held by TCG LP, and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson (the "Managing Partners"). The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

F3: Represents a change in the form of ownership of TCG GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F4: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F5: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F6: The securities are directly held by Peter Svennilson

F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F8: The securities are directly held by David Goeddel.

F9: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F10: The securities are directly held by Tim Kutzkey.

F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG GP to its general and limited partners.

F12: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.

F13: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.

F14: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.

F15: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners.

F16: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are the Managing Partners. The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

F17: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP.

F18: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F19: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its general and limited partners.

F20: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F21: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F22: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F23: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"), and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

F24: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"), and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

RAPT Therapeutics, Inc.

Report date December 23, 2024 · Filed December 23, 2024

Jointly reported with COLUMN GROUP II, LP, Column Group II GP, LP, PONOI CAPITAL, LP, Ponoi Capital II, LP, Ponoi II Management, LLC, Kutzkey Tim, GOEDDEL DAVID V, Svennilson Peter, Column Group LLC

Section 16 reporting ended · disclosed 2024-12-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	50,000	Reported balance After 2024-12-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-12-23 · Other · Disposed 1,352,008 · Balance 50,000 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-12-23 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2024-12-23 · Other · Disposed 1,599,417 · Balance 0 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,236,261	Reported balance Holding disclosure · report date 2024-12-23 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,236,261 F4: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	42,189	Reported balance Holding disclosure · report date 2024-12-23 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 42,189 F5: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	163	Reported balance Holding disclosure · report date 2024-12-23 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 163 F6: The securities are directly held The Column Group LLC ("TCG LLC"). The managing members of TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee footnote	145,401	Reported balance Holding disclosure · report date 2024-12-23 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 145,401 F7: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	1,352,008	Reported balance After 2024-12-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-12-23 · Other · Acquired 1,352,008 · Balance 1,352,008 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee footnote	1,599,417	Reported balance After 2024-12-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-12-23 · Other · Acquired 1,599,417 · Balance 1,599,417 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F4: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F5: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F6: The securities are directly held The Column Group LLC ("TCG LLC"). The managing members of TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F7: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 18, 2021 Filed Aug 20, 2021 16:35 UTC	RAPT Therapeutics, Inc. RAPT · Entity 62554	OtherCommon Stock	91	$0.00	$0.00	Disclosure SEC source: 0000899243-21-033833 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 91 F7 · kind: Represents a change in the form of ownership of The Column Group, LLC ("TCG LLC") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F8 · ownership.nature: The securities are directly held TCG LLC. The managing members of TCG LLC are the TCG II GP Managing Partners and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
August 18, 2021 Filed Aug 20, 2021 16:35 UTC	RAPT Therapeutics, Inc. RAPT · Entity 62554	OtherCommon Stock	208,403	$0.00	$0.00	Disclosure SEC source: 0000899243-21-033833 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F6 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its partners. F5 · ownership.nature: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the TCG II Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
August 18, 2021 Filed Aug 20, 2021 16:35 UTC	RAPT Therapeutics, Inc. RAPT · Entity 62554	OtherCommon Stock	208,403	$0.00	$0.00	Disclosure SEC source: 0000899243-21-033833 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 208,403 F4 · kind: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP. F5 · ownership.nature: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the TCG II Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
August 18, 2021 Filed Aug 20, 2021 16:35 UTC	RAPT Therapeutics, Inc. RAPT · Entity 62554	OtherCommon Stock	1,317,005	$0.00	$0.00	Disclosure SEC source: 0000899243-21-033833 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Column Group LLC · CIK 0001833486 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,568,674 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners. F2 · balance_after: Includes shares previously reported as held by The Column Group II Management, LP. F3 · ownership.direct: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	7,752	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 15 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,406 F22 · kind: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F10 · ownership.nature: The securities are directly held by Tim Kutzkey. Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	17,829	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 14 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 139,383 F21 · kind: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F8 · ownership.nature: The securities are directly held by David Goeddel. Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	17,829	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 13 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 134,010 F20 · kind: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F6 · ownership.nature: The securities are directly held by Peter Svennilson Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	49,689	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 12 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F19 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its general and limited partners. F18 · ownership.nature: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	49,689	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 11 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,689 F17 · kind: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP. F18 · ownership.nature: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	1,000,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 10 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 989,000 F15 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners. F16 · ownership.nature: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are the Managing Partners. The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	30,347	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 9 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 40,654 F14 · kind: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP. F10 · ownership.nature: The securities are directly held by Tim Kutzkey. Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	111,247	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 8 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 121,554 F13 · kind: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP. F8 · ownership.nature: The securities are directly held by David Goeddel. Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	105,874	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 7 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 116,181 F12 · kind: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP. F6 · ownership.nature: The securities are directly held by Peter Svennilson Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	438,338	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 6 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F11 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG GP to its general and limited partners. F4 · ownership.nature: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	10,307	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 5 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,307 F9 · kind: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F10 · ownership.nature: The securities are directly held by Tim Kutzkey. Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	10,307	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,307 F7 · kind: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F8 · ownership.nature: The securities are directly held by David Goeddel. Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	10,307	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,307 F5 · kind: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F6 · ownership.nature: The securities are directly held by Peter Svennilson Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	438,338	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 438,338 F3 · kind: Represents a change in the form of ownership of TCG GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F4 · ownership.nature: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
May 05, 2021 Filed May 7, 2021 20:40 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	OtherCommon Stock	2,000,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-018761 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,394,333 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group, LP ("TCG LP") to its general and limited partners. F2 · ownership.direct: The securities are directly held by TCG LP, and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson (the "Managing Partners"). The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
February 17, 2021 Filed Feb 19, 2021 17:31 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	SaleCommon Stock	10,000	$36.95	$369,503.00	Disclosure SEC source: 0000899243-21-007420 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 99,155 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $36.95 to $37.005, inclusive. The David V. and Alena Z. Goeddel 2004 Trust undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: These securities are held directly by The David V. and Alena Z. Goeddel 2004 Trust. Read SEC document
December 14, 2020 Filed Dec 16, 2020 18:40 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	OtherWarrant (right to buy) · Derivative	30,107	$0.00 Strike: $1.55	$0.00	Disclosure SEC source: 0000899243-20-034164 · doc4.xml · derivative · entry 7 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,107 shares Expires 2021-05-24 F7 · derivative.exercise_date: This warrant was fully exercisable as of the date of the Issuer's initial public offering. F1 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"). The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
December 14, 2020 Filed Dec 16, 2020 18:40 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	OtherCommon Stock	30,107	$1.55	$46,665.85	Disclosure SEC source: 0000899243-20-034164 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,584,957 F1 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"). The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	1,075,133	$36.40	$39,134,841.20	Disclosure SEC source: 0000899243-20-031483 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,429,180 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	952,023	$36.40	$34,653,637.20	Disclosure SEC source: 0000899243-20-031483 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner GOEDDEL DAVID V · CIK 0001182464 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,151,026 F1 · ownership.direct: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson, a member of the Issuer's board of directors, and Tim Kutzkey (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares Read SEC document
September 22, 2020 Filed Sep 23, 2020 16:52 UTC	RAPT Therapeutics, Inc. RAPT · Entity 62554	SaleCommon Stock	608,000	$30.85	$18,756,800.00	Disclosure SEC source: 0001209191-20-051673 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Column Group II Management, LP · CIK 0001783952 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,835,679 F1 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
September 02, 2020 Filed Sep 3, 2020 17:31 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	27,595	$17.67	$487,603.65	Disclosure SEC source: 0001209191-20-049487 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,827,025 F4 · shares: Consists of 12,960 shares of Common Stock held directly by TCG III LP and 14,635 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
September 01, 2020 Filed Sep 3, 2020 17:31 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	36,494	$17.64	$643,754.16	Disclosure SEC source: 0001209191-20-049487 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,799,430 F1 · shares: Consists of 17,139 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 19,355 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 28, 2020 Filed Aug 31, 2020 17:00 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	26,135	$17.89	$467,555.15	Disclosure SEC source: 0001209191-20-048798 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,762,936 F4 · shares: Consists of 12,274 shares of Common Stock held directly by TCG III LP and 13,861 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 27, 2020 Filed Aug 31, 2020 17:00 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	36,359	$17.79	$646,826.61	Disclosure SEC source: 0001209191-20-048798 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,736,801 F1 · shares: Consists of 17,075 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 19,284 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 25, 2020 Filed Aug 25, 2020 18:50 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	100	$18.00	$1,800.00	Disclosure SEC source: 0001209191-20-048294 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700,442 F5 · shares: Consists of 47 shares of Common Stock held directly by TCG III LP and 53 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 24, 2020 Filed Aug 25, 2020 18:50 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	11,024	$17.96	$197,991.04	Disclosure SEC source: 0001209191-20-048294 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700,342 F4 · shares: Consists of 5,177 shares of Common Stock held directly by TCG III LP and 5,847 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 21, 2020 Filed Aug 25, 2020 18:50 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	7,321	$17.97	$131,558.37	Disclosure SEC source: 0001209191-20-048294 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,689,318 F1 · shares: Consists of 3,438 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 3,883 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 17, 2020 Filed Aug 17, 2020 19:11 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	6,425	$17.89	$114,943.25	Disclosure SEC source: 0001209191-20-046992 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,681,997 F5 · shares: Consists of 3,017 shares of Common Stock held directly by TCG III LP and 3,408 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 17, 2020 Filed Aug 19, 2020 17:39 UTC	RAPT Therapeutics, Inc. RAPT · Entity 62554	SaleCommon Stock	538,654	$22.75	$12,254,378.50	Disclosure SEC source: 0001209191-20-047573 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Column Group II Management, LP · CIK 0001783952 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,443,679 F1 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
August 14, 2020 Filed Aug 17, 2020 19:11 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	37,993	$17.49	$664,497.57	Disclosure SEC source: 0001209191-20-046992 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,675,572 F4 · shares: Consists of 17,843 shares of Common Stock held directly by TCG III LP and 20,150 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
August 13, 2020 Filed Aug 17, 2020 19:11 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	19,895	$17.89	$355,921.55	Disclosure SEC source: 0001209191-20-046992 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,637,579 F1 · shares: Consists of 9,343 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 10,552 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 30, 2020 Filed Aug 3, 2020 17:54 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	732	$17.99	$13,168.68	Disclosure SEC source: 0001209191-20-044543 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,617,684 F1 · shares: Consists of 344 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 388 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionSeries D Preferred Stock · Derivative	686,274	$0.00	$0.00	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · derivative · entry 12 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 686,274 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F5 · ownership.direct: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"), and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionSeries D Preferred Stock · Derivative	686,274	$0.00	$0.00	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · derivative · entry 11 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 686,274 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F4 · ownership.direct: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"), and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionSeries B Preferred Stock · Derivative	1,989,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · derivative · entry 10 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,989,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F3 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionSeries B Preferred Stock · Derivative	1,836,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · derivative · entry 9 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,836,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionSeries A-2 Preferred Stock · Derivative	875,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · derivative · entry 8 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 875,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionSeries A-1 Preferred Stock · Derivative	600,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · derivative · entry 7 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionCommon Stock	686,274	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · nonDerivative · entry 6 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F5 · ownership.direct: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"), and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionCommon Stock	686,274	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · nonDerivative · entry 5 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F4 · ownership.direct: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"), and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionCommon Stock	1,989,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,989,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F3 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionCommon Stock	1,836,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,394,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionCommon Stock	875,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,558,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionCommon Stock	600,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 683,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 30, 2020 19:23 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	4,105	$17.99	$73,848.95	Disclosure SEC source: 0001209191-20-044067 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,616,952 F1 · shares: Consists of 1,928 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 2,177 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.